Novavax INC 8-K filings

Novavax reported a substantial year-over-year revenue decrease for Q2 2026, but raised its full-year revenue framework and improved expense guidance, driven by partnership advancements.

Novavax reported a significant decrease in first-quarter 2026 revenue, largely due to the prior year's non-cash sales, but highlighted substantial growth in strategic partnerships and licensing agreements.

Novavax reported a significant financial turnaround in 2025, achieving net income and securing a major licensing agreement with Pfizer for its Matrix-M adjuvant.

Novavax, Inc. entered into a License and Option Agreement with Pfizer Inc. for its Matrix-M™ adjuvant technology, potentially generating over $530 million in upfront and milestone payments plus royalties.

Novavax details a strategic transformation at J.P. Morgan, focusing on partnerships, R&D innovation, and a path to non-GAAP profitability by 2028, alongside preliminary 2025 financial insights.

Novavax reports third-quarter 2025 financial results, highlighting strong Sanofi partnership milestones, significant cost savings from Maryland site consolidation, and an increased full-year revenue framework.

Novavax completed the transfer of U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi, triggering a $25 million milestone payment.

Novavax, Inc. has entered into agreements to assign its Gaithersburg facility lease, sell land, and assets to AstraZeneca, expecting $59.8 million in proceeds and a non-cash impairment charge.

Novavax announced the completion of Nuvaxovid EU marketing authorization transfer to Sanofi, triggering a $25 million milestone payment.

Novavax, Inc. issued $225 million in new 4.625% Convertible Senior Notes due 2031, extending debt maturity and raising additional cash.

Novavax's Nuvaxovid 2025-2026 Formula COVID-19 vaccine has received U.S. FDA approval for individuals 65 and older, or those 12-64 with high-risk underlying conditions.

Novavax, Inc. announced a significant debt refinancing, exchanging most of its 2027 convertible notes for new 2031 notes and raising $49.7 million in new cash.

Novavax reports $239 million in Q2 2025 revenue, driven by FDA approval of Nuvaxovid and a $175 million milestone payment from Sanofi, while advancing its vaccine pipeline.

Novavax, Inc. announced the results of its Annual Meeting held on June 20, 2025, where stockholders re-elected three Class III directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as the independent auditor for fiscal year 2025.

Novavax, Inc. announced robust immune responses and favorable tolerability from the initial cohort of its Phase 3 COVID-19-Influenza Combination and stand-alone influenza vaccine candidates, alongside a new corporate growth strategy focused on R&D and diversified partnerships, including a significant collaboration with Sanofi.

Novavax, Inc. announced the elimination of its Chief Operating Officer position, leading to the termination of John Trizzino's employment effective June 20, 2025, with a separation package and a subsequent consulting agreement.

Novavax receives FDA approval for its COVID-19 vaccine Nuvaxovid, triggering a $175 million milestone payment from Sanofi and prompting a new postmarketing commitment (PMC) trial.

Novavax announced positive Q1 2025 financial results, driven by revenue recognition from terminated agreements, and raised its full-year revenue guidance, highlighting progress in its partnership with Sanofi and pipeline development.

Novavax and Takeda revise their existing agreement, granting Takeda more flexibility in vaccine strain selection and updating financial terms.

Novavax appoints Charles W. Newton to its Board of Directors, increasing the board size to nine members, effective April 25, 2025.

Novavax expresses confidence in the approvability of its Biologics License Application (BLA) for its COVID-19 vaccine based on discussions with the FDA, while addressing a request for post-marketing commitment (PMC) data.

Novavax confirms it has addressed all FDA information requests for its COVID-19 vaccine BLA and is awaiting the agency's decision.

Novavax announces the retirement of James Young as Chair of the Board, the appointment of Margaret McGlynn as his successor, and the addition of John Shiver as an independent director.

Novavax's advanced purchase agreement with Canada for its COVID-19 vaccine has been terminated due to the company not receiving regulatory approval by the agreed-upon deadline, leading to an expected $576 million revenue recognition in Q1 2025.

Novavax is shifting its focus towards research and development and strategic partnerships, particularly with Sanofi, to drive future growth and value creation.

Novavax announced its Q4 and full year 2024 financial results, highlighting the transition of its COVID-19 vaccine lead to Sanofi and progress in its pipeline programs.

Novavax reaffirmed its full-year 2024 financial guidance and provided updates on its strategic partnerships, pipeline development, and cost reduction efforts.

Novavax finalized the sale of its Czech Republic biologics manufacturing campus to Novo Nordisk for a total consideration of $200 million, including cash and assumed liabilities.

Novavax has amended its supply agreement with Australia, crediting $31 million for canceled COVID-19 vaccine doses and updating the delivery schedule through 2029.

Novavax has agreed to sell its biologics manufacturing campus in the Czech Republic to Novo Nordisk for $200 million, including the assumption of certain liabilities.